{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:04:11Z","timestamp":1790193851631,"version":"4.1.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jcf.2019.12.004","type":"journal-article","created":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T20:28:14Z","timestamp":1577219294000},"page":"e7-e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["To be or not to be on CFTR modulators during pregnancy: Risks to be considered"],"prefix":"10.1016","volume":"19","author":[{"given":"Sona","family":"Vekaria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Popowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhain","family":"Mulrennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2019.12.004_bib0001","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jcf.2015.12.019","article-title":"CFTR modulators and pregnancy: our work has only just begun","volume":"15","author":"Goss","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2019.12.004_bib0002","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcf.2017.11.009","article-title":"Drugs during pregnancy and breastfeeding in women diagnosed with cystic fibrosis \u2013 An update","volume":"17","author":"Kroon","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2019.12.004_bib0003","series-title":"Respiratory disease in pregnancy. obstetrics: normal respiratory disease in pregnancies [Internet]","author":"Whitty","year":"2017"},{"key":"10.1016\/j.jcf.2019.12.004_bib0004","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A cftr potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2019.12.004_bib0005","unstructured":"Vertex Pharmaceuticals. Kalydeco (Ivacaftor) [prescribing information]. U.S. food and drug administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/203188s029,207925s008lbl.pdf. Revised April 2019. Accessed October 20, 2019."}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919931930983X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919931930983X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:42:40Z","timestamp":1761601360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156919931930983X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S156919931930983X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2019.12.004","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"To be or not to be on CFTR modulators during pregnancy: Risks to be considered","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2019.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}